1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biotechnology in Belgium

Biotechnology in Belgium

  • February 2015
  • -
  • MarketLine
  • -
  • 38 pages

Introduction

Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2010-14, and forecast to 2019). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium biotechnology market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology industry consists of the development, manufacturing, and industrying of products based on advanced biotechnology research.

*The Belgian biotechnology industry had total revenues of $7.8bn in 2014, representing a compound annual growth rate (CAGR) of 7% between 2010 and 2014.

*The medical/healthcare segment was the industry's most lucrative in 2014, with total revenues of $6.0bn, equivalent to 76.4% of the industry's overall value.

*The performance of the industry is forecast to accelerate, with an anticipated CAGR of 8.8% for the five-year period 2014 - 2019, which is expected to drive the industry to a value of $11.9bn by the end of 2019.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the biotechnology market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Belgium

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Key Questions Answered

What was the size of the Belgium biotechnology market by value in 2014?

What will be the size of the Belgium biotechnology market in 2019?

What factors are affecting the strength of competition in the Belgium biotechnology market?

How has the market performed over the last five years?

Table Of Contents

Biotechnology in Belgium
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
AstraZeneca PLC 19
Novartis AG 22
Sanofi SA 26
ThromboGenics NV 30
Macroeconomic Indicators 33
Country Data 33
Methodology 35
Industry associations 36
Related MarketLine research 36
Appendix 37
About MarketLine 37

LIST OF TABLES
Table 1: Belgium biotechnology industry value: $ billion, 2010-14(e) 8
Table 2: Belgium biotechnology industry category segmentation: $ billion, 2014(e) 9
Table 3: Belgium biotechnology industry geography segmentation: $ billion, 2014(e) 10
Table 4: Belgium biotechnology industry value forecast: $ billion, 2014-19 11
Table 5: AstraZeneca PLC: key facts 19
Table 6: AstraZeneca PLC: key financials ($) 20
Table 7: AstraZeneca PLC: key financial ratios 20
Table 8: Novartis AG: key facts 22
Table 9: Novartis AG: key financials ($) 23
Table 10: Novartis AG: key financial ratios 24
Table 11: Sanofi SA: key facts 26
Table 12: Sanofi SA: key financials ($) 27
Table 13: Sanofi SA: key financials (€) 27
Table 14: Sanofi SA: key financial ratios 28
Table 15: ThromboGenics NV: key facts 30
Table 16: ThromboGenics NV: key financials ($) 30
Table 17: ThromboGenics NV: key financials (€) 31
Table 18: ThromboGenics NV: key financial ratios 31
Table 19: Belgium size of population (million), 2010-14 33
Table 20: Belgium gdp (constant 2005 prices, $ billion), 2010-14 33
Table 21: Belgium gdp (current prices, $ billion), 2010-14 33
Table 22: Belgium inflation, 2010-14 34
Table 23: Belgium consumer price index (absolute), 2010-14 34
Table 24: Belgium exchange rate, 2010-14 34

LIST OF FIGURES
Figure 1: Belgium biotechnology industry value: $ billion, 2010-14(e) 8
Figure 2: Belgium biotechnology industry category segmentation: % share, by value, 2014(e) 9
Figure 3: Belgium biotechnology industry geography segmentation: % share, by value, 2014(e) 10
Figure 4: Belgium biotechnology industry value forecast: $ billion, 2014-19 11
Figure 5: Forces driving competition in the biotechnology industry in Belgium, 2014 12
Figure 6: Drivers of buyer power in the biotechnology industry in Belgium, 2014 13
Figure 7: Drivers of supplier power in the biotechnology industry in Belgium, 2014 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Belgium, 2014 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Belgium, 2014 17
Figure 10: Drivers of degree of rivalry in the biotechnology industry in Belgium, 2014 18
Figure 11: AstraZeneca PLC: revenues and profitability 21
Figure 12: AstraZeneca PLC: assets and liabilities 21
Figure 13: Novartis AG: revenues and profitability 24
Figure 14: Novartis AG: assets and liabilities 25
Figure 15: Sanofi SA: revenues and profitability 28
Figure 16: Sanofi SA: assets and liabilities 29
Figure 17: ThromboGenics NV: revenues and profitability 31
Figure 18: ThromboGenics NV: assets and liabilities 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.